Keros Therapeutics price target raised to $28 from $11 at Wells Fargo

Wells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the shares. The safety findings announced in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, “basically zeroed expectations,” though cash plus pipeline is worth more than where the stock is right now, the analyst tells investors in a research note.